Japan Launches Remote GPU Experiment for AI Drug Discovery
TOKYO, JAPAN, 17th February , 2025 – The joint demonstration experiment on the remote provision of GPU compute power concerning AI drug discovery has been commenced at Shonan iPark by Mitsubishi Corporation, NTT, NTT Communications, Morgenrot Inc., and iPark Institute. The project uses NTT’s IOWN APN technology along with virtualization solutions from Morgenrot to not only improve AI analysis capabilities but also share data securely and wisely cost-wise in pharmaceutical research.
Drug discovery by itself would take decades, with lots of testing and analysis involved; nevertheless, AI could help speed up the breakthrough, but infrastructure costs, arbitrarily high-security verifications, and sheer delays in data transfer oftentimes become real hurdles. Thus, this newly launched initiative would work to bypass existing limitations by allowing researchers to perform high-speed, secure AI computations without resorting to public cloud storage.
The experiment interlinks the Shonan iPark R&D facility with the NRT10 data center operated by MC Digital Realty. NTT is employing NVIDIA state-of-the-art GPU offerings to facilitate AI processing for gene analyses, protein structure prediction, and drug compound modeling seamlessly. The collaboration will test the network performance, AI workload efficiency, and security standards in terms of scalability that will apply to industrial AI applications.
With the establishment of a high-speed, low-latency computation environment, this initiative fortifies Japan’s claim to fame in AI-led pharmaceutical research. Growths in the future may expand the indicated potential to different industries to provide secure and remote access to advanced computational power.
Read Latest Stories:
Ericsson and ACES-NH Introduce Shared 5G Indoor Connectivity in Saudi Arabia
AI Spending in Asia Pacific Set to Surge, Driving $1.6 Trillion
Fixstars Partners with OPTAGE to Develop a High-Performance AI Data Center
